Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RGS4 | P49798 | 1/20 | 0.40 |
| ▸ | RGS8 | P57771 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16541518 | 0.85 | KDM4E (0.40) | ALDH1A1KDM4EMGLLMAPK14 | |
| SCHEMBL12311153 | 0.84 | TYR (0.46) | CMA1ALDH1A1KDM4ENR1H3GSK3A | |
| SCHEMBL14532059 | 0.82 | ALDH1A1 (0.51) | CMA1ALDH1A1KDM4EMGLLMAPK14 | |
| SCHEMBL10059426 | 0.82 | MGLL (0.44) | ALDH1A1KDM4EMGLLMAPK14POLB | |
| SCHEMBL10079855 | 0.79 | ALDH1A1 (0.41) | ALDH1A1KDM4EMGLLRGS4RGS8 | |
| SCHEMBL16104141 | 0.79 | METAP2 (0.40) | CMA1ALDH1A1 | |
| SCHEMBL146809 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KDM4ETP53RGS4RGS8 | |
| SCHEMBL10059427 | 0.78 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPK14 | |
| SCHEMBL10059425 | 0.78 | KMT2A (0.39) | ALDH1A1KDM4EGSK3AGSK3BKCNH2 | |
| SCHEMBL758900 | 0.77 | ALDH1A1 (0.62) | ALDH1A1KDM4EMGLLMAPK14POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010536-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9527816-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2591784-B1 | Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system | INTERMUNE INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20140228310-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8741936-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2591784-A1 | Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system | Intermune, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120258924-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-2426134-A2 | Method of modulating stress-activated protein kinase system | Intermune, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | UNIVERSITY OF MINNESOTA (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010135470-A1 | PIFENIDONE DERIVATIVES FOR TREATING BRONCHIAL ASTHMA | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010132864-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | INTERMUNE, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100240704-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010085805-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-7728013-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2007062167-A9 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE INC (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007062167-A2 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | TNNI3, FABP3, TNNT2 | CMA1 154/4885ALDH1A1 94/4885KDM4E 2408/4885 |
| US-20100240704-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | CMA1 3045/4885ALDH1A1 3375/4885KDM4E 3655/4885 |
| US-10010536-B2 | Method of modulating stress-activated protein kinase system | MAPKAPK2, MAP3K6, MAP4K1 | CMA1 3045/4885ALDH1A1 3375/4885KDM4E 3655/4885 |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | CMA1 3045/4885ALDH1A1 3375/4885KDM4E 3655/4885 |
| US-20140228310-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | CMA1 3045/4885ALDH1A1 3375/4885KDM4E 3655/4885 |
| US-20120258924-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | CMA1 3045/4885ALDH1A1 3375/4885KDM4E 3655/4885 |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | MMP1, MMP8, CCL11 | CMA1 456/4885ALDH1A1 358/4885KDM4E 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.